NCT05122559View on ClinicalTrials.gov

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Multiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
Interventions
DRUG

N-acetyl cysteine

N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.

DRUG

Placebo

Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF

Trial Locations (1)

94158

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Emmanuelle Waubant, MD PhD

OTHER